|
Canada Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Canada Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Canada.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Canadian pharmaceutical and healthcare industry.
Competitive intelligence, Canadian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Canadian market.
The Canada Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Canada Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Canadian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Canada to test other views – a key input for successful budgeting and strategic business planning in the Canadian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Canadian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Canada.
- Exploit The Latest Competitive Canadian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Canada.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Canada Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Canada Pharmaceuticals And Healthcare Industry SWOT |
| Canada Political SWOT |
| Canada Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Regional Pharma Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Canada – Market Summary |
| Regulatory Regime |
| Pricing Regime And Reimbursement Issues |
| Reimbursement Regime |
| Recent Pricing and Reimbursement Developments |
Chapter - Industry Developments |
| Epidemiology |
| Healthcare Sector |
| Health Expenditure |
| Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators |
| National Pharmaceuticals Strategy |
| Pharmaceutical Industry |
| Recent Company Activity |
| Pharmaceutical Re-import Policy |
| Research And Development Sector |
| Biotechnology |
| Medical Devices Industry |
| Recent Developments In The Medical Devices Industry |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Canada – Drug Market Indicators, Historical Data And Forecasts |
| Key Growth Factors – Industry |
| Table: Canada – Health Expenditure Indicators, Historical Data And Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Canada – Economic Activity |
| Prescription Market Forecast |
| Table: Canada – Prescription Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Patented Market Forecast |
| Table: Canada - Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Canada - Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Canada – OTC Market Indicators, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Canada - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Devices Forecast |
| Table: Canada – Medical Device Market Forecast, Historical Data And Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data |
| Table: Canada – Other Health And Healthcare Indicators, Historical Data And Forecasts |
Chapter - Competitive Landscape |
| Table: Canada's Leading Generics Firms, 2006 |
Chapter - Company Profiles |
| Leading Multinational Manufacturers |
| Pfizer |
| Merck & Co |
| GlaxoSmithKline |
| Sanofi-Aventis |
| Novartis |
| Indigenous Manufacturers |
| Apotex |
Chapter - Country Snapshot: Canada Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2000-2003 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Canada Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In BMI’s Business Environment Rankings for Q209, Canada is once again placed third out of the 10 markets surveyed in the Americas region, having been overtaken by Puerto Rico in Q408. Canada is ranked joint 9th in global terms, alongside South Korea, despite having received a slightly lower score than in the previous quarter. Overall, the value of the Canadian CAD26bn (US$25bn) market at consumer prices is expected to rise to just CAD29.9bn (US$24.1bn) in 2013, implying a low compound annual growth rate (CAGR) of 2.8%. The worsening of its position is mainly a function of the slowdown of the growth of its pharmaceutical market, which is negatively impacted by patent expirations and government driven cut-backs on drug spending. Additionally, regulatory shortcomings have in the past been responsible for no-launches of some innovative medicines, with approvals experiencing considerable delays.
Canada spent CAD15.7 (US$15.1bn) on patented drugs in 2008, as pharmaceutical products worth US$1.2bn lost patent protection in 2007, around four times the value of the expected patent expiries in 2008 and 2009. According to IMS Health, the number of new molecular entities (NMEs) launched in Canada in 2007 accounted for less that 0.3% of total sales. Moreover, the patented medicine price index revealed that manufacturers’ prices fell by 0.2% in 2006 after four years of consecutive growth. However, BMI believes that the proposed system of progressive licensing that shifts the focus from pre-market review to ongoing post-market evaluations should improve the position of patented drugs. If implemented, the changes should help remove some of the regulatory hurdles for experimental new drugs, although critics claim that in effect consumers will be used like ‘guinea pigs’.
In economic terms, Canada is also experiencing a marked slowdown, with BMI pencilling in a 1.4% real GDP contraction in 2009. The key to Canada's economic health is the US, and on that front, we are seeing increasing downside risks, which in turn put our Canadian forecasts in jeopardy. Although we have not seen the same signs of economic decline in Canada as we have recognised in the US, in both countries, economic indicators are pointing toward a potentially prolonged and deep recession. We are currently forecasting a mild rebound in H209 but Canada will find it difficult to avoid a negative full-year figure. This outlook will have clear implications for the Canadian healthcare market, given that public funding accounts for some 70% of the total expenditure.
On a positive note for medical devices manufacturers, in February 2009, the Government of Ontario, extended a US$29.6mn grant to Agfa HealthCare from its Next Generation of Jobs Fund. The fund aims to both support existing jobs and create some 100 new positions. However, BMI notes that nearly 87% of all research and development (R&D) jobs are already located in Quebec and Ontario, with the two provinces therefore highly vulnerable to economic downturn. Additionally, the strength of the Canadian dollar against the US dollar has caused problems for the export-focused manufacturing industry, which has also had to contend with the emergence of lower-cost manufacturing bases (such as Mexico), making investment in hi-tech medical devices all the more necessary.
|
Canada Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |